Literature DB >> 28580712

Kawasaki disease: State of the art.

Jane W Newburger1.   

Abstract

Kawasaki disease is an acute febrile arteritis of childhood that can result in coronary artery aneurysms if untreated in the first 10 and ideally 7 days of illness. Kawasaki disease begins as a necrotizing arteritis with neutrophilic infiltrate, followed by subacute/chronic changes and luminal myofibroblastic proliferation that can cause coronary artery stenosis. Manifestations include the presence of ≥5 days of fever, together with clinical criteria of extremity changes, rash, conjunctivitis, oral changes, and unilateral cervical lymphadenopathy. Echocardiography should be performed at the time of diagnosis, then 1-2 weeks and 4-6 weeks later, with more frequent studies in individuals with coronary artery dilation or persistent fever. Coronary artery dimensions are characterized both as z-scores and absolute measurements, and coronary architecture evolves over time in children who have aneurysms in the first weeks of illness. Systematic follow-up and therapies are tailored to the degree of coronary disease and to coronary ischemia.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Kawasaki disease; arteritis; coronary aneurysm; myocardial ischemia

Mesh:

Year:  2017        PMID: 28580712     DOI: 10.1111/chd.12498

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  2 in total

1.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

2.  A retrospective cohort study of major adverse cardiac events in children affected by Kawasaki disease with coronary artery aneurysms in Thailand.

Authors:  Kanokvalee Santimahakullert; Chodchanok Vijarnsorn; Yuttapong Wongswadiwat; Prakul Chanthong; Sappaya Khrongsrattha; Manat Panamonta; Paradorn Chan-On; Kritvikrom Durongpisitkul; Paweena Chungsomprasong; Supaluck Kanjanauthai; Jarupim Soongswang
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.